Online inquiry

IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1570MR)

This product GTTS-WQ1570MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets BMP10&GDF2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_014482.3; NM_016204.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27302; 2658
UniProt ID O95393; Q9UK05
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1570MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15794MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ14697MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SCT-400
GTTS-WQ12092MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ4639MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ13269MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-06252616
GTTS-WQ8848MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ2078MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AIN457
GTTS-WQ5770MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW